Skip to main content

Advertisement

Log in

Single agent vinorelbine in pediatric patients with progressive optic pathway glioma

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

The management of progressive unresectable low-grade glioma remains controversial. Treatment options have included radiotherapy, and more recently chemotherapy, usually following an initial period of observation. Within this context, we evaluated vinorelbine, a semi-synthetic vinca alkaloid that has shown evidence of activity against glioma. From July 2007 an institutional protocol with vinorelbine (30 mg/m2 days 0, 8, 22) for a total of 18 cycles, has been conducted at IOP/GRAACC/UNIFESP for children with optic pathway glioma (OPG). The main objectives were clinical and radiological response, as well as toxicity profile. Twenty-three patients with progressive OPG with a mean age of 69 months (4–179) were enrolled. Three patients had a diagnosis of neurofibromatosis type 1. Twenty-two patients were assessable for response with an overall objective response rate of 63 %, with eight patients showing stable disease. The most important toxicity was hematologic (grade III/IV neutropenia) observed in four patients. Gastrointestinal toxicity (grade I/II vomiting) was observed in seven patients and only 1 patient showed grade I peripheral neuropathy. The median progression-free survival (PFS) was 33 months (6.9–69) with a 3 and 5 year PFS of 64 ± 19 and 37 ± 20 %, respectively, for an overall 3 and 5 year-survival of 95 ± 10 %. This study suggests that vinorelbine may be an interesting option for pediatric low-grade gliomas, showing low toxicity profile and providing a good quality of life for patients with such chronic disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. CBTRUS (2000–2004) Statistical report: primary brain tumors in the United States. 2000–2004, the central brain tumor. Registry of the United States, Hinsdale

  2. Medlock MD, Scott RM (1997) Optic chiasm astrocytomas of childhood. 2. Surgical management. Pediatr Neurosurg 27(3):129–136

    Article  CAS  PubMed  Google Scholar 

  3. Gajjar A, Sanford RA, Heideman R, Jenkins JJ, Walter A, Li Y et al (1997) Low-grade astrocytoma: a decade of experience at St. Jude Children’s Research Hospital. J Clin Oncol 15(8):2792–2799

    CAS  PubMed  Google Scholar 

  4. Watson GA, Kadota RP, Wisoff JH (2001) Multidisciplinary management of pediatric low-grade gliomas. Semin Radiat Oncol 11(2):152–162

    Article  CAS  PubMed  Google Scholar 

  5. Grabenbauer GG, Schuchardt U, Buchfelder M, Rödel CM, Gusek G, Marx M et al (2000) Radiation therapy of optico-hypothalamic gliomas (OHG)–radiographic response, vision and late toxicity. Radiother Oncol 54(3):239–245

    Article  CAS  PubMed  Google Scholar 

  6. Grill J, Couanet D, Cappelli C, Habrand JL, Rodriguez D, Sainte-Rose C, Kalifa C (1999) Radiation-induced cerebral vasculopathy in children with neurofibromatosis and optic pathway glioma. Ann Neurol 45(3):393–396

    Article  CAS  PubMed  Google Scholar 

  7. Perilongo G (2005) Considerations on the role of chemotherapy and modern radiotherapy in the treatment of childhood low grade glioma. J Neurooncol 75(3):301–307

    Article  PubMed  Google Scholar 

  8. Packer RJ, Lange B, Ater J, Nicholson HS, Allen J, Walker R et al (1993) Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol 11(5):850–856

    CAS  PubMed  Google Scholar 

  9. Packer RJ, Ater J, Allen J, Phillips P, Geyer R, Nicholson HS et al (1997) Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 86(5):747–754

    Article  CAS  PubMed  Google Scholar 

  10. Prados MD, Edwards MS, Rabbitt J, Lamborn K, Davis RL, Levin VA et al (1997) Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen. J Neurooncol 32(3):235–241

    Article  CAS  PubMed  Google Scholar 

  11. Gururangan S, Cavazos CM, Ashley D, Herndon JE 2nd, Bruggers CS, Moghrabi A et al (2002) Phase II study of carboplatin in children with progressive low-grade gliomas. J Clin Oncol 20(13):2951–2958

    Article  CAS  PubMed  Google Scholar 

  12. Massimino M, Spreafico F, Cefalo G, Riccardi R, Tesoro-Tess JD, Gandola L et al (2002) High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J Clin Oncol 20(20):4209–4216

  13. Fouladi M, Hunt DL, Pollack IF, Dueckers G, Burger PC, Becker LE et al (2003) Outcome of children with centrally reviewed low-grade gliomas treated with chemotherapy with or without radiotherapy on Children’s Cancer Group high-grade glioma study CCG-945. Cancer 98(6):1243–1252

    Article  PubMed  Google Scholar 

  14. Massimino M, Spreafico F, Riva D, Biassoni V, Poggi G, Solero C et al (2010) A lower-dose, lower-toxicity cisplatin-etoposide regimen for childhood progressive low-grade glioma. J Neurooncol 100(1):65–71

    Article  CAS  PubMed  Google Scholar 

  15. Gururangan S, Fisher MJ, Allen JC, Herndon JE 2nd, Quinn JA, Reardon DA et al (2007) Temozolomide in children with progressive low-grade glioma. Neuro Oncol 9(2):161–168

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Packer RJ, Jakacki R, Horn M, Rood B, Vezina G, MacDonald T et al (2009) Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer 52(7):791–795

    Article  PubMed  Google Scholar 

  17. Lafay-Cousin L, Holm S, Qaddoumi I, Nicolin G, Bartels U, Tabori U et al (2005) Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction. Cancer 103(12):2636–2642

    Article  CAS  PubMed  Google Scholar 

  18. Bouffet E, Jakacki R, Goldman S, Hargrave D, Hawkins C, Shroff M et al (2012) Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol 30(12):1358–1363

    Article  CAS  PubMed  Google Scholar 

  19. Rosenstock JG, Evans AE, Schut L (1976) Response to vincristine of recurrent brain tumors in children. J Neurosurg 45(2):135–140

    Article  CAS  PubMed  Google Scholar 

  20. Casanova M, Ferrari A, Spreafico F, Terenziani M, Massimino M, Luksch R et al (2002) Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma. Cancer 94(12):3263–3268

    Article  CAS  PubMed  Google Scholar 

  21. Casanova M, Ferrari A, Bisogno G, Merks JH, De Salvo GL, Meazza C et al (2004) Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol. Cancer 101(7):1664–1671

    Article  CAS  PubMed  Google Scholar 

  22. Hanley ML, Elion GB, Colvin OM, Modrich PL, Keir S, Adams DJ et al (1998) Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors. Cancer Chemother Pharmacol 42(6):479–482

    Article  CAS  PubMed  Google Scholar 

  23. Johansen M, Kuttesch J, Bleyer WA, Krailo M, Ames M, Madden T et al (2006) Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children’s Oncology Group. Clin Cancer Res 12(2):516–522

    Article  CAS  PubMed  Google Scholar 

  24. Cappellano AM, Bouffet E, Cavalheiro S, Seixas MT, da Silva NS et al (2011) Diffuse intrinsic brainstem tumor in an infant: a case of therapeutic efficacy with vinorelbine. J Pediatr Hematol Oncol 33(2):116–118

    Article  PubMed  Google Scholar 

  25. Qaddoumi I, Sultan I, Broniscer A (2009) Pediatric low-grade gliomas and the need for new options for therapy: why and how? Cancer Biol Ther 8(1):4–10

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Avery RA, Fisher MJ, Liu GT (2011) Optic pathway gliomas. J Neuroophthalmol 31(3):269–278

    Article  PubMed  Google Scholar 

  27. Steinbok P, Hentschel S, Almqvist P, Cochrane DD, Poskitt K et al (2002) Management of optic chiasmatic/hypothalamic astrocytomas in children. Can J Neurol Sci 29(2):132–138

    PubMed  Google Scholar 

  28. Nicolin G, Parkin P, Mabbott D, Hargrave D, Bartels U, Tabori U et al (2009) Natural history and outcome of optic pathway gliomas in children. Pediatr Blood Cancer 53(7):1231–1237

    Article  PubMed  Google Scholar 

  29. Ater JL, Zhou T, Holmes E, Mazewski CM, Booth TN, Freyer DR et al (2012) Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children’s Oncology Group. J Clin Oncol 30(21):2641–2647

    Article  PubMed Central  PubMed  Google Scholar 

  30. Kuttesch JF Jr, Krailo MD, Madden T, Johansen M, Bleyer A, Children’s Oncology Group (2009) Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a Children’s Oncology Group study. Pediatr Blood Cancer 53(4):590–593

    Article  PubMed Central  PubMed  Google Scholar 

  31. Biassoni V, Casanova M, Spreafico F, Gandola L, Massimino M et al (2006) A case of relapsing glioblastoma multiforme responding to vinorelbine. J Neurooncol 80(2):195–201

    Article  CAS  PubMed  Google Scholar 

  32. Scheinemann K, Bartels U, Tsangaris E, Hawkins C, Huang A, Dirks P et al (2011) Feasibility and efficacy of repeated chemotherapy for progressive pediatric low-grade gliomas. Pediatr Blood Cancer 57(1):84–88

    Article  PubMed  Google Scholar 

  33. Rodriguez FJ, Lim KS, Bowers D, Eberhart CG (2013) Pathological and molecular advances in pediatric low-grade astrocytoma. Annu Rev Pathol 8:361–379

  34. Avery RA, Bouffet E, Packer RJ, Reginald A (2013) Feasibility and comparison of visual acuity testing methods in children with neurofibromatosis type 1 and/or optic pathway gliomas. Invest Ophthalmol Vis Sci 54(2):1034–1038

  35. Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ et al (2012) Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol 14(6):790–797

    Article  PubMed Central  PubMed  Google Scholar 

  36. Moreno L, Bautista F, Ashley S, Duncan C, Zacharoulis S (2010) Does chemotherapy affect the visual outcome in children with optic pathway glioma? A systematic review of the evidence. Eur J Cancer 46(12):2253–2259

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Andrea Maria Cappellano.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cappellano, A.M., Petrilli, A.S., da Silva, N.S. et al. Single agent vinorelbine in pediatric patients with progressive optic pathway glioma. J Neurooncol 121, 405–412 (2015). https://doi.org/10.1007/s11060-014-1652-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-014-1652-6

Keywords

Navigation